- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Collaborators
- Suppliers
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- Research centres
- People
- Alistair Brown
- Anne-Laure Puaux
- Assoc Prof Joanna Groom
- Associate Profesor Ian Majewski
- Associate Professor Aaron Jex
- Associate Professor Andrew Webb
- Associate Professor Chris Tonkin
- Associate Professor Diana Hansen
- Associate Professor Edwin Hawkins
- Associate Professor Ethan Goddard-Borger
- Associate Professor Gemma Kelly
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Vince
- Associate Professor Jason Tye-Din
- Associate Professor Jeanne Tie
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor John Wentworth
- Associate Professor Justin Boddey
- Associate Professor Kate Sutherland
- Associate Professor Kelly Rogers
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Melissa Call
- Associate Professor Misty Jenkins
- Associate Professor Nawaf Yassi
- Associate Professor Oliver Sieber
- Associate Professor Rachel Wong
- Associate Professor Rhys Allan
- Associate Professor Rosie Watson
- Associate Professor Ruth Kluck
- Associate Professor Shalin Naik
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Tracy Putoczki
- Chela Niall
- Deborah Carr
- Dr Alisa Glukhova
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Belinda Phipson
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Brad Sleebs
- Dr Drew Berry
- Dr Gwo Yaw Ho
- Dr Hamish King
- Dr Hui-Li Wong
- Dr Jacqui Gulbis
- Dr Jim Whittle
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Nadia Davidson
- Dr Nadia Kershaw
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Rory Bowden
- Dr Samir Taoudi
- Dr Sarah Best
- Dr Saskia Freytag
- Dr Shabih Shakeel
- Dr Sheau Wen Lok
- Dr Stephin Vervoort
- Dr Yunshun Chen
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Kaye Wycherley
- Keely Bumsted O'Brien
- Mr Mark Eaton
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Lew
- Professor Andrew Roberts
- Professor Anne Voss
- Professor Clare Scott
- Professor Daniel Gray
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor James McCarthy
- Professor James Murphy
- Professor Jane Visvader
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leanne Robinson
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marc Pellegrini
- Professor Marco Herold
- Professor Marnie Blewitt
- Professor Matthew Ritchie
- Professor Melanie Bahlo
- Professor Melissa Davis
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Czabotar
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Sandra Nicholson
- Professor Sant-Rayn Pasricha
- Professor Seth Masters
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Papenfuss
- Professor Wai-Hong Tham
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Clinician-scientist training
- Undergraduate
- Student research projects
- A multi-pronged approach to targeting myeloproliferative neoplasms
- A new paradigm of machine learning-based structural variant detection
- A whole lot of junk or a treasure trove of discovery?
- Advanced imaging interrogation of pathogen induced NETosis
- Analysing the metabolic interactions in brain cancer
- Atopic dermatitis causes and treatments
- Building a cell history recorder using synthetic biology for longitudinal patient monitoring
- Characterisation of malaria parasite proteins exported into infected liver cells
- Deciphering the heterogeneity of the tissue microenvironment by multiplexed 3D imaging
- Defining the mechanisms of thymic involution and regeneration
- Delineating the molecular and cellular origins of liver cancer to identify therapeutic targets
- Developing computational methods for spatial transcriptomics data
- Developing drugs to block malaria transmission
- Developing models for prevention of hereditary ovarian cancer
- Developing statistical frameworks for analysing next generation sequencing data
- Development and mechanism of action of novel antimalarials
- Development of novel RNA sequencing protocols for gene expression analysis
- Discoveries in red blood cell production and function
- Discovery and targeting of novel regulators of transcription
- Dissecting host cell invasion by the diarrhoeal pathogen Cryptosporidium
- Dissecting mechanisms of cytokine signalling
- Doublecortin-like kinases, drug targets in cancer and neurological disorders
- Epigenetic biomarkers of tuberculosis infection
- Exploiting cell death pathways in regulatory T cells for cancer immunotherapy
- Exploiting the cell death pathway to fight Schistosomiasis
- Finding treatments for chromatin disorders of intellectual disability
- Functional epigenomics in human B cells
- How do nutrition interventions and interruption of malaria infection influence development of immunity in sub-Saharan African children?
- Human lung protective immunity to tuberculosis
- Improving therapy in glioblastoma multiforme by activating complimentary programmed cell death pathways
- Innovating novel diagnostic tools for infectious disease control
- Integrative analysis of single cell RNAseq and ATAC-seq data
- Interaction with Toxoplasma parasites and the brain
- Interactions between tumour cells and their microenvironment in non-small cell lung cancer
- Investigation of a novel cell death protein
- Malaria: going bananas for sex
- Mapping spatial variation in gene and transcript expression across tissues
- Multi-modal computational investigation of single-cell communication in metastatic cancer
- Nanoparticle delivery of antibody mRNA into cells to treat liver diseases
- Naturally acquired immune response to malaria parasites
- Organoid-based discovery of new drug combinations for bowel cancer
- Organoid-based precision medicine approaches for oral cancer
- Removal of tissue contaminations from RNA-seq data
- Reversing antimalarial resistance in human malaria parasites
- Role of glycosylation in malaria parasite infection of liver cells, red blood cells and mosquitoes
- Screening for novel genetic causes of primary immunodeficiency
- Statistical analysis of single-cell multi-omics data
- Structural and functional analysis of epigenetic multi-protein complexes in genome regulation
- Structure, dynamics and impact of extra-chromosomal DNA in cancer
- Targeted deletion of disease-causing T cells
- Targeting cell death pathways in tissue Tregs to treat inflammatory diseases
- The cellular and molecular calculation of life and death in lymphocyte regulation
- The role of hypoxia in cell death and inflammation
- The role of ribosylation in co-ordinating cell death and inflammation
- Understanding Plasmodium falciparum invasion of red blood cells
- Understanding cellular-cross talk within a tumour microenvironment
- Understanding the genetics of neutrophil maturation
- Understanding the roles of E3 ubiquitin ligases in health and disease
- Unveiling the heterogeneity of small cell lung cancer
- Using combination immunotherapy to tackle heterogeneous brain tumours
- Using intravital microscopy for immunotherapy against brain tumours
- Using nanobodies to understand malaria invasion and transmission
- Using structural biology to understand programmed cell death
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Andrew Baldi
- Anna Gabrielyan
- Ashley Weir
- Bridget Dorizzi
- Casey Ah-Cann
- Catia Pierotti
- Emma Nolan
- Huon Wong
- Jasmine Rou
- Jing Deng
- Joy Liu
- Kaiseal Sarson-Lawrence
- Komal Patel
- Krishneel Prasa
- Lilly Backshell
- Malvika Kharbanda
- Megan Kent
- Naomi Jones
- Pailene Lim
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Runyu Mao
- Sarah Garner
- Simona Seizova
- Sophie Collard
- Wayne Cawthorne
- Wil Lehmann
- Yanxiang Meng
- Zhong Yan Gan
- Miles Horton
- Alexandra Gurzau
- Student achievements
- Student association
- Learning Hub
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- WEHI.TV
Cicada Innovations to operate new biotech incubator to drive translation of world-class medical research
3 November 2022
CSL, WEHI, and the University of Melbourne have announced the appointment of an independent operator to oversee and manage a new start-up incubator that will support and grow early-stage Australian biotech companies.
At a glance
-
CSL, WEHI and The University of Melbourne jointly announce the appointment of Cicada Innovations as the independent operator of a new biotech incubator which will be located in CSL’s new Global Headquarters currently under construction in the Melbourne Biomedical Precinct.
-
Cicada’s appointment as operator follows the project partners joining forces to create an incubator and commercial wet lab space for biotech start-up companies, with the Victorian Government’s landmark Breakthrough Victoria Fund providing funding to support the $95 million project.
- It will be Australia’s first and only incubator that is co-located with a leading biopharmaceutical company, providing all of the wrap-around support that start-ups need to translate Australian medical research into new treatments and therapies.
Cicada Innovations, a Sydney-based deep-tech incubator, will be responsible for establishing operations and overseeing day-to-day management of the incubator and its residents.
The incubator, to be located at CSL’s new global corporate headquarters under construction in the Melbourne Biomedical Precinct, will support start-up companies to translate promising medical research into commercial outcomes.
Drawing on experience
Experienced in establishing and running incubators in Australia, Cicada was selected following a competitive global search.
corporate headquarters currently under construction
in the Melbourne Biomedical Precinct.
Cicada has a successful track record of supporting ventures to create life-changing technology by applying cutting-edge science and a strong national presence coupled with global reach.
Twice named ‘top incubator in the world’ by International Business Incubator Association, Cicada has helped incubated start-ups raise over $1.5 billion in funding, achieve over $1.3 billion in exits and trade sales, file over 600 patents, and launch over 700 innovations globally.
WEHI Director, Professor Doug Hilton AO said that the appointment of Cicada is an important step forward for the incubator.
“The incubator is vital for building a critical mass of management-skilled scientists who have the knowledge and confidence to run successful biomed and biotech companies,” he said.
“Ultimately the incubator will accelerate translational outputs to take scientific discoveries to the next stage of development faster.
“Cicada’s unique experience, underpinned by a wealth of knowledge about Australia’s biotech ecosystem and the unique challenges facing start-ups here, will provide a launchpad for incubator residents to translate medical research to successful commercial outcomes.”
Dr Andrew Nash, CSL’s Chief Scientific Officer and Senior Vice President, Research, said, “Incubator residents will be working in an innovation-driven environment alongside a large and focused CSL R&D team, enabling opportunities for peer-collaboration, learning and sharing of ideas.”
Sally-Ann Williams, CEO Cicada Innovations, said: “Global health challenges require collaboration between all parts of the ecosystem to bring solutions to market.
“The opportunity to connect Australia’s world leading biomedical research with the support needed to translate discoveries to products in market is one that will benefit Australia as a whole.
“This incubator can be a catalyst nationally for growth in commercial biotech outcomes for Australia and we are delighted to help bring that vision to life.”
Role of the incubator operator
The incubator will be open to applications from small biotech companies who have engaged in early research and are seeking to take their discoveries to the next stage of development.
Operated by Cicada, the incubator will provide affordable, state-of-the-art wet-lab facilities, equipment and office space to start-ups.
Cicada will provide a range of services, including commercialisation education programs, facilitated access to investors, industry mentoring and access to service providers for incubator residents, ensuring the creation and ongoing success of a vibrant biotech ecosystem within the incubator.
University of Melbourne Deputy Vice-Chancellor (Research) Professor Jim McCluskey said the appointment of Cicada, with its depth of experience and understanding of the support required by research scientists to nurture biomedical start-ups, was substantial progress in establishing Australia’s leading incubator.
“Once the incubator is operational it will accelerate the translation of promising medical research into biotech inventions and commercial outcomes, provoking new collaborations while addressing the challenges facing the community,” Professor McCluskey said.
Community of support
Made possible with financial and in-kind support from CSL, one of the world’s largest biotech companies, University of Melbourne and WEHI, together with investment partner Breakthrough Victoria, an independent company managing the $2 billion Breakthrough Victoria Fund, the incubator is scheduled to open to start-ups in 2024 and will be able to accommodate up to 40 early-stage companies from around Australia and internationally.
CSL’s Chief Scientific Officer, Dr Andrew Nash, said incubator residents will benefit from Cicada’s operational expertise and proven track record of incubator management as well as its location within CSL’s new Global headquarters and Australian R&D hub.
“The strong collaboration between CSL, the University of Melbourne, WEHI, Breakthrough Victoria and now Cicada Innovations has been critical to bring the incubator to fruition and reflects CSL’s values and desire to deliver on our promise to patients worldwide.
“As Australia’s largest biotech, we can share our extensive knowledge with resident biotech start-ups who will have access to the wrap around support they need to translate their medical research into new treatments and therapies,” he said.
About the biotech incubator
Incubators reduce barriers to entry for start-ups through an affordable ‘one-stop shop’ that provides access to expert technical support and sophisticated technology platforms which can be expensive and cost-prohibitive to small companies. Start-ups that are incubated have a much higher five-year survival rate and accelerated growth trajectory compared with standalone entities.
Many of Australia’s greatest medical research breakthroughs have been built upon national collaborations. This incubator will build on this history and will be open to all high-quality early-stage spinouts from the precinct, across Victoria, around Australia and internationally.
Breakthrough Victoria CEO Grant Dooley said: “Breakthrough Victoria is proud to be investing in the biotech incubator, which will give start-ups access to industry expertise and specialised lab and clinical facilities and infrastructure to develop and commercialise their innovations.”
Located over two floors of CSL’s new corporate headquarters being built in the Melbourne Biomedical Precinct, the incubator will have one floor of purpose-built wet lab space and another for meetings, office and collaboration space.
There, the incubator will be embedded alongside seven floors of leading-edge laboratory and clinical manufacturing space supporting CSL’s own R&D program, in which the company has invested more than US$1 billion globally the past fiscal year.
The incubator is expected to open by early 2024 and welcomes expressions of interest from start-ups across Australia and internationally.
Start-ups interested in applying for residence in the incubator are encouraged to email incubator@csl.com.au.
Media enquiries
M: +61 475 751 811
E: communications@wehi.edu.au
Super Content:
Want to hear about our latest discoveries? Subscribe to our supporter newsletter, Illuminate.